Case 2: Double Refractory Patient with High-risk Cytogenetics
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts